Asterric Acid
(Synonyms: 曲地酸,Dimethylosoic Acid,RES-1214-1,TAN 1415A) 目录号 : GC16216
An antiangiogenic agent
Cas No.:577-64-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 10 μM for ET-1 binding to the ETA receptor ofA10 cells
Asterric Acid is an ETA receptor inhibitor.
Endothelin (ET), a potent vasoconstrictor/pressor peptide consisting of 21 amino acid residues, was first isolated from the cultures of porcine aortic endothelial cells. Analyses of a human genomic library reveals three forms of ET (ET-1, ET-2 and ET-3) with more than 70% homology with one another. In various organs, high affinity and specific receptors for ET have been found, which have been classfied as receptors ETA and ETB. ET-1 has potent and long-lasting vasoconstrictive activity, as a result of binding to the ETA receptor.
In vitro: Previous study asterric acid isolated as an active substance from the culture filtrate of a fungus, Aspergillus sp. Asterric acid had also been reported as a metabolite of a fungus. It was found that asterric acid had the property of inhibiting ET-1 binding to the ETA receptor of A10 cells, but it showed no inhibitory activity against ANP and A II binding at 10 mM, which indicated that asterric acid displayed as a specific inhibitor of ET-1 binding [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Ohashi, H. ,Akiyama, H.,Nishikori, K., et al. Asterric acid, a new endothelin binding inhibitor. Journal of Antibiotics 45, 1684-1685 (1992).
| Cas No. | 577-64-0 | SDF | |
| 别名 | 曲地酸,Dimethylosoic Acid,RES-1214-1,TAN 1415A | ||
| 化学名 | 2-(2-carboxy-3-hydroxy-5-methylphenoxy)-5-hydroxy-3-methoxy-benzoic acid, 1-methyl ester | ||
| Canonical SMILES | CC1=CC(O)=C(C(O)=O)C(OC2=C(OC)C=C(O)C=C2C(OC)=O)=C1 | ||
| 分子式 | C17H16O8 | 分子量 | 348.3 |
| 溶解度 | Soluble in ethanol;Soluble in DMSO;Soluble in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8711 mL | 14.3554 mL | 28.7109 mL |
| 5 mM | 0.5742 mL | 2.8711 mL | 5.7422 mL |
| 10 mM | 0.2871 mL | 1.4355 mL | 2.8711 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。